High expression of nucleobindin 2 is associated with poor prognosis in gastric cancer
Bolag Altan,
Kyoichi Kaira,
Shuichi Okada,
Tsugumichi Saito,
Eijiro Yamada,
Halin Bao,
Pinjie Bao,
Kengo Takahashi,
Takehiko Yokobori,
Oyama Tetsunari,
Masahiko Nishiyama,
Masanobu Yamada
Affiliations
Bolag Altan
Department of Oncology Clinical Development, Graduate School of Medicine, Gunma University, Maebashi, Japan
Kyoichi Kaira
Department of Oncology Clinical Development, Graduate School of Medicine, Gunma University, Maebashi, Japan
Shuichi Okada
Department of Medicine and Molecular Science, Graduate School of Medicine, Gunma University, Maebashi, Japan
Tsugumichi Saito
Department of Medicine and Molecular Science, Graduate School of Medicine, Gunma University, Maebashi, Japan
Eijiro Yamada
Department of Medicine and Molecular Science, Graduate School of Medicine, Gunma University, Maebashi, Japan
Halin Bao
Department of General Surgical Science, Graduate School of Medicine, Gunma University, Maebashi, Japan
Pinjie Bao
Department of General Surgical Science, Graduate School of Medicine, Gunma University, Maebashi, Japan
Kengo Takahashi
Department of Thoracic and Visceral Organ Surgery, Graduate School of Medicine, Gunma University, Maebashi, Japan
Takehiko Yokobori
Research Program for Omics-based Medical Science, Division of Integrated Oncology Research, Gunma University Initiative for Advanced Research, Maebashi, Japan
Oyama Tetsunari
Department of Diagnostic Pathology, Graduate School of Medicine, Gunma University, Maebashi, Japan
Masahiko Nishiyama
Department of Molecular Pharmacology and Oncology, Graduate School of Medicine, Gunma University, Maebashi, Japan
Masanobu Yamada
Department of Medicine and Molecular Science, Graduate School of Medicine, Gunma University, Maebashi, Japan
Nucleobindin 2 has been reported that its high expression is associated with poor outcome and promotes cell migration and lymph node metastasis in breast cancer, colon cancer, and prostate cancer. However, we aimed to investigate the nucleobindin 2 expression in gastric cancer tissues and adjacent non-tumor tissues and its potential relevance to clinicopathological factors and prognosis using immunohistochemical analysis. In our study, nucleobindin 2 level in gastric cancer tissues was higher than in non-tumor tissues. A high expression of nucleobindin 2 is significantly associated with tumor depth, lymph node metastasis, lymphatic invasion, venous invasion, and clinical stage. Furthermore, the expression level of nucleobindin 2 protein was independent predictor of progression-free survival. In summary, nucleobindin 2 might play a crucial role in gastric cancer development and could serve as an independent predictor of prognosis of gastric cancer patients.
